

Officers:

Edward J. Lee, President
 Mattielee V. Tatum, Vice President
 Valley Cargo International Inc., 7032
 N.W. 50 Street, Miami, FL 33166

Officers:

Rodrigo Rincon, Director
 Victor Hugo Sierra, Owner
 Seaborne International, Inc., 11222 La
 Cienega Boulevard, Suite 620,
 Inglewood, CA 90304

Officers:

Steven A. Robinson, President
 Brian Anstey, Executive Vice
 President

Dated: April 17, 1997.

Joseph C. Polking,

Secretary.

[FR Doc. 97-10547 Filed 4-22-97; 8:45 am]

BILLING CODE 6730-01-M

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 16, 1997.

A. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

1. Community Financial Corp., Edgewood, Iowa; to acquire up to 100 percent of the voting shares of Community Savings Bank, Robins, Iowa.

B. Federal Reserve Bank of Minneapolis (Karen L. Grandstrand, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480-2171:

1. First Bank System, Inc., Minneapolis, Minnesota; to merge with U.S. Bancorp, Portland, Oregon, and thereby indirectly acquire U.S. National Bank of Oregon, Portland, Oregon; U.S. Bank of Washington, N.A., Seattle, Washington; U.S. Bank of Nevada, Reno, Nevada; U.S. Bank of Utah, Salt Lake City, Utah; U.S. Bank of Idaho, Boise, Idaho; U.S. Bank of California, Sacramento, California; First State Bank of Oregon, Canby, Oregon; Sun Capital Bank, St. George, Utah; and Business & Professional Bank, Woodland, California.

In connection with this application, Applicant also has applied to acquire West One Trust Company d/b/a U.S. Bank Trust Company, Salt Lake City, Utah; LNB Corp., Alameda, California; and U.S. Bank Trust Company, Portland, Oregon, and thereby engage in personal and institutional trust and fiduciary activities, pursuant to § 225.25(b)(3) of the Board's Regulation Y; U.S. Bancorp Insurance Agency, Inc., Portland, Oregon, and thereby engage in insurance agency activities, pursuant to §§ 225.25(b)(8)(i) and (vii) of the Board's Regulation Y; U.S. Trade Services, Inc., Portland, Oregon, and thereby engage in letter of credit issuing and paying and related letter of credit processing activities, pursuant to § 225.25(b)(1)(iv) of the Board's Regulation Y; West One Life Insurance Company, Portland, Oregon, and thereby indirectly engage in credit reinsurance activities, pursuant to § 225.25(b)(8)(i) of the Board's Regulation Y; CBI Mortgage, Modesto, California, and thereby engage in mortgage banking activities, pursuant to § 225.25(b)(1)(iii) of the Board's Regulation Y; Compass Group, Inc., Spokane, Washington, and thereby engage in investment advisory services, pursuant to § 225.25(b)(4) of the Board's Regulation Y; Island Bancorp Leasing, Inc., Alameda, California, and thereby engage in leasing and equipment financing, pursuant to § 225.25(b)(5) of the Board's Regulation Y. Applicant also has applied to acquire numerous partnerships and thereby engage in community development activities, pursuant to § 225.25(b)(6) of the Board's Regulation Y. Applicant also has applied pursuant to § 211.33(a) of the Board's Regulation K to acquire U.S. Trade Corporation, Portland, Oregon.

Board of Governors of the Federal Reserve System, April 17, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97-10480 Filed 4-22-97; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 11:00 a.m., Monday, April 28, 1997.

PLACE: Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 21st Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452-3204. You may call (202) 452-3207, beginning at approximately 5 p.m. two business days before this meeting, for a recorded announcement of bank and bank holding company applications scheduled for the meeting.

Dated: April 18, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97-10581 Filed 4-18-97; 8:45 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Agency Information Collection Activities: Proposed Collections; Comment Request

The Department of Health and Human Services, Office of the Secretary will periodically publish summaries of proposed information collection projects and solicit public comments in compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995. To request more information on the project or to obtain a copy of the information collection plans and instruments, call the OS Reports Clearance Officer on (202) 690-6207.

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Projects: Public Health Service Acquisition Regulation—PHSAR Part 380—Special Program Requirements Affecting PHS Acquisitions, and Part 352—Solicitation Provisions and Contract Clauses—0990-0128—Extension—This clearance request addresses recordkeeping and reporting requirements in the Public Health Service Acquisition Regulation (PHSAR) for acquisitions involving safety and health, drugs and medical supplies, reusable cylinders, laboratory animals and the Indian Self-Determination Act. *Respondents:* State or local governments, Businesses or other for-profit, non-profit institutions, Small businesses; *Burden Information for Drugs and Medical Supplies—Total Number of Respondents:* 50; *Annual Frequency of Response:* three times; *Average Burden per Response:* 2 hours; *Estimated Annual Burden for Drugs and Medical Supplies Requirement:* 300 hours—Burden Information for Indian Self-Determination Act—*Total Number of Respondents:* 591; *Annual Frequency of Response:* one time; *Average Burden per Response:* 2 hours; *Estimated Annual Burden for Indian Self-Determination Act Requirement:* 1,182 hours—Burden Information for Reusable Cylinders—*Total Number of Respondents:* 16; *Annual Frequency of Response:* five times; *Average Burden per Response:* 1 hour; *Estimated Annual Burden for Reusable Cylinders Requirement:* 80 hours—Burden Information for Laboratory Animals—*Total Number of Respondents:* 51; *Annual Frequency of Response:* one time; *Average Burden per Response:* 10 hours; *Estimated Annual Burden for Laboratory Animals Requirement:* 510 hours—Burden Information for Safety and Health—*Total Number of Respondents:* 59; *Annual Frequency of Response:* one time; *Average Burden per Response:* 8 hours; *Estimated Annual Burden for Health and Safety Requirement:* 472 hours—Burden Information for Additional Payment

Provisions—Total Number of Respondents: 454; *Annual Frequency of Response:* three times; *Average Burden per Response:* 1 hour; *Estimated Annual Burden for Additional Payment Requirement:* 1,362 hours—*Total Burden:* 3,906 hours.

Send comments to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue S.W., Washington, DC 20201. Written comments should be received within 60 days of this notice.

Dated: April 15, 1997.

Dennis P. Williams,

Deputy Assistant Secretary, Budget.

[FR Doc. 97-10503 Filed 4-22-97; 8:45 am]

BILLING CODE 4150-04-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Nonprescription Drugs Advisory Committee with Representation from the Endocrinologic and Metabolic Drugs Advisory Committee.

General Function of the Committee: The committee reviews and evaluates available data concerning the safety and effectiveness of over-the-counter (nonprescription) human drug products for use in the treatment of a broad spectrum of human symptoms and diseases.

Date and Time: The meeting will be held on May 13, 1997, 8:30 a.m. to 5 p.m. An open public hearing portion is scheduled from 8:30 a.m. to 9:30 a.m.

Location: Holiday Inn—Bethesda, Versailles Ballrooms I and II, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Andrea Neal or Angie Whitacre, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-5455, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12541. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will hear presentations and discuss data

submitted regarding the switch from prescription to over-the-counter status of new drug application (NDA) 16-640/S072, Questran® Powder (cholestyramine resin) and NDA 19-669/S020, Questran® Light (cholestyramine resin with aspartame), Bristol Myers Squibb, for the reduction of elevated serum cholesterol.

Procedure: The meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by May 8, 1997. Those desiring to make formal presentations should notify the contact person before May 8, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: April 17, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97-10476 Filed 4-22-97; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of the Committee: Peripheral and Central Nervous System Drugs Advisory Committee.

General Function of the Committee: The committee reviews and evaluates data on the safety and effectiveness of marketed and investigational human drugs for use in neurological disease.

Date and Time: The meeting will be held on May 8, 1997, 8:30 a.m. to 5 p.m. An open public hearing portion is scheduled from 1 p.m. to 2 p.m.

Location: Holiday Inn—Bethesda, Versailles Ballrooms I, II, and III, 8120 Wisconsin Ave., Bethesda, MD.

Contact Person: Ermona B. McGoodwin or Danyiel D'Antonio,